Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.
Null
Donald
D
Primary Children's Medical Center, Salt Lake City, UT, USA.
Pollara
Bernard
B
Dennehy
Penelope H
PH
Steichen
Jean
J
Sánchez
Pablo J
PJ
Givner
Laurence B
LB
Carlin
David
D
Landry
Bernard
B
Top
Franklin H
FH
Connor
Edward
E
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000097:blood / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage / Q000097:blood / Q000276:immunology*; D004311:Double-Blind Method; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007273:Injections, Intramuscular; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000592:standards*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology*; D012449:Safety; D012621:Seasons; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D022261:Respiratory Syncytial Virus Vaccines; D000069455:Palivizumab